Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €113.02 EUR
Change Today -0.70 / -0.62%
Volume 0.0
As of 2:32 AM 05/25/15 All times are local (Market data is delayed by at least 15 minutes).

vertex pharmaceuticals inc (VX1) Snapshot

Open
€113.07
Previous Close
€113.73
Day High
€113.07
Day Low
€113.02
52 Week High
03/20/15 - €126.28
52 Week Low
06/20/14 - €46.96
Market Cap
27.5B
Average Volume 10 Days
239.9
EPS TTM
--
Shares Outstanding
243.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERTEX PHARMACEUTICALS INC (VX1)

vertex pharmaceuticals inc (VX1) Related Businessweek News

View More BusinessWeek News

vertex pharmaceuticals inc (VX1) Details

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF); and advancing its research and early-stage development programs. It markets KALYDECO (ivacaftor) to treat patients of six years of age and older with CF who have the mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene in the United States, Australia, Canada, and the European Union. The company also provides INCIVEK for the treatment of adults with genotype 1 hepatitis C virus infection. In addition, it is developing CFTR correctors, including lumacaftor in combination with ivacaftor, which has completed Phase III development program; and VX-661 in combination with ivacaftor, which is in Phase III development program. Further, it identifies and develops next-generation CFTR corrector compounds; and is involved in the research and early-stage development programs, including programs in the areas of oncology and neurology. Vertex Pharmaceuticals Incorporated sells its products principally to specialty pharmacy providers and wholesalers in North America, as well as government-owned and supported customers in international markets. The company has collaboration agreements with Cystic Fibrosis Foundation Therapeutics Incorporated; BioAxone Biosciences, Inc.; and Janssen Pharmaceuticals, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

1,830 Employees
Last Reported Date: 02/13/15
Founded in 1989

vertex pharmaceuticals inc (VX1) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.1M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $650.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $789.1K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $600.0K
Special Counsel to the Chief Executive Office...
Total Annual Compensation: $465.0K
Compensation as of Fiscal Year 2014.

vertex pharmaceuticals inc (VX1) Key Developments

Vertex Pharmaceuticals Incorporated Receives U.S. Food and Drug Administration Approval for ORKAMBITM for Use in People with Cystic Fibrosis

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administrations (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted 12 to 1 to recommend that the FDA approve ORKAMBITM (lumacaftor/ivacaftor) for use in people with cystic fibrosis (CF) ages 12 and older who have two copies of the F508del mutation in the CFTR gene. Advisory committees provide the FDA with independent scientific and medical advice on safety, effectiveness and appropriate use of potential new medicines. The FDA is expected to make a decision on the approval of ORKAMBI by July 5, 2015 under the Prescription Drug User Fee Act (PDUFA). The FDA is not bound by the committee's recommendation but often follows its advice. If approved, ORKAMBI will be the first and only medicine to treat the underlying cause of CF for eligible people with CF ages 12 and older with two copies of the F508del mutation in the CFTR gene. People with two copies of the F508del mutation represent the largest group of people with CF. There are approximately 8,500 people ages 12 and older with two copies of the F508del mutation in the U.S.

Vertex Pharmaceuticals Incorporated Proposes Amendment to Restated Articles of Organization

Vertex Pharmaceuticals Incorporated at its AGM to be held on June 4, 2015, proposed amendment to restated articles of organization to increase the number of shares of common stock available for issuance from 300 million to 500 million.

Vertex Pharmaceuticals Incorporated Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Vertex Pharmaceuticals Incorporated announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of $138,509,000 against $118,451,000 a year ago. Loss from operations was $171,985,000 against $216,042,000 a year ago. Loss from continuing operations before provision for income taxes was $198,405,000 against $231,308,000 a year ago. Loss from continuing operations attributable to Vertex was $198,606,000 or $0.83 per basic and diluted share against $232,111,000 or $1.00 per basic and diluted share a year ago. Net loss attributable to Vertex was $198,606,000 or $0.83 per basic and diluted share against $232,457,000 or $1.00 per basic and diluted share a year ago. Non-GAAP net loss attributable to Vertex was $148,376,000 or $0.62 per basic and diluted share against $151,394,000 or $0.65 per basic and diluted share a year ago. Non-GAAP total revenues were $135,440,000 against $108,210,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VX1:GR €113.02 EUR -0.70

VX1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $61.35 USD -0.45
BioMarin Pharmaceutical Inc $127.19 USD +0.31
Incyte Corp $107.69 USD -0.72
Jazz Pharmaceuticals PLC $183.06 USD +2.28
Pharmacyclics Inc $261.25 USD +1.70
View Industry Companies
 

Industry Analysis

VX1

Industry Average

Valuation VX1 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 49.9x
Price/Book 31.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 47.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERTEX PHARMACEUTICALS INC, please visit www.vrtx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.